Spotlight Featured Researcher Jonathan Bricker. With cutting-edge psychology and technology, he helps millions adopt healthy habits and reduce their cancer risk.
This report on Diversity, Equity and Inclusion at Fred Hutch documents the initiatives, progress, programming, events and reflections from the 2020-2021 year. Pause, reflect and reengage as we build on our foundation of critical change to actualize the Fred Hutch mission.
Blood Test for 50 Cancers Coming to US Clinics Soon medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Biostatisticians draft blueprints for COVID-19 vax trials
Hutch group applies skills honed during decades of HIV prevention trials to bring about safe and effective vaccines for a new pandemic February 18, 2021 • By Sabin Russell / Fred Hutch News Service
Dr. Peter Gilbert (left) leads a team of Fred Hutch biostatisticians that pivoted to COVID-19 vaccine trial design. Dr. Holly Janes (right) is a co-principal investigator with Gilbert at the Statistical and Data Management Center for the HIV Vaccine Trials Network.
Dr. Peter Gilbert (top) leads a team of Fred Hutch biostatisticians that pivoted to COVID-19 vaccine trial design. Dr. Holly Janes (below) is a co-principal investigator with Gilbert at the Statistical and Data Management Center for the HIV Vaccine Trials Network.
Date Time
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment
Reston, VA-Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called
18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy.
Nearly two-thirds of invasive breast cancers are ER-positive, and endocrine therapy is the mainstay of treatment for these tumors because of its favorable toxicity profile and efficacy. Should cancer progress in these patients, however, salvage endocrine therapy with molecularly targeted agents or chemotherapy can help.